Progress in Acute Myeloid Leukemia: Adapting Treatment to Individual Patients

Table of Contents

 
  • Program Overview
    Progress in Acute Myeloid Leukemia: Adapting Treatment to Individual Patients
    In this online educational program, CCO’s expert faculty explore optimal care for patients with AML, including predictive/prognostic factors to consider in selecting treatment for AML, management of newly diagnosed AML, treatment of relapsed/refractory disease and novel agents that may affect care in the near future.

Latest Content

2 of 2 Shown
  • How I Use New Targeted Agents to Improve Outcomes for My Patients With AML

    B. Douglas Smith MD - 10/12/2017
    Here are my thoughts on how best to apply the recently approved targeted agents gemtuzumab ozogamicin, midostaurin, and enasidenib to improve outcomes for your patients with acute myeloid leukemia.
  • How Newly Approved CPX-351 Will Change AML Treatment

    Jeffrey E. Lancet MD - 9/28/2017 2 comments / Last Comment: 10/11/2017
    CPX-351 is beginning to replace traditional 3+7 chemotherapy for secondary or high-risk AML. Learn what you need to know to use it effectively in the clinic.
2 of 2 Shown
Show 0 More
Loading...